AbbVie (ABBV) sues Trump administration to narrow drug discount patient definition, via Axios

AbbVie's lawsuit against the Trump administration to narrow the drug discount patient definition could have significant implications for pharmaceutical pricing policies. If successful, this move may impact how drug discounts are applied, potentially affecting the company's revenue and broader industry practices. Traders should consider the regulatory risks and cost structures in biotech, as well as potential ripple effects on other players in the sector.